Loading
NASDAQHealthcareMedical - Diagnostics & Research
Latest quote
$15.78
−$0.03 · -0.19%
Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome's first commercial-stage test, SimpleScreen CRC for colorectal cancer, is under review by the U.S. Food and Drug Administration (FDA).
Previous close
$15.78
−$0.03 · -0.19%
Regular session · ET · Market data may be delayed.
Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome's first commercial-stage test, SimpleScreen CRC for colorectal cancer, is under review by the U.S. Food and Drug Administration (FDA).
Day range
Current $15.78
52-week range
Current $15.78
Regular session · ET · Market data may be delayed.
Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome's first commercial-stage test, SimpleScreen CRC for colorectal cancer, is under review by the U.S. Food and Drug Administration (FDA).
Day range
Current $15.78
52-week range
Current $15.78
Third-party consensus; not a GoAI recommendation.
Average target
$18.25
15.65% upsideFunds reporting this stock among their holdings, ordered by reported position size.
ARK Genomic Revolution ETFARKG14.69M0.72%1.56B USD0.75%$51.30+4.08%
Schwab U.S. Small-Cap ETFSCHA4.46M0.02%21.82B USD0.03%$32.79+0.40%
iShares Core S&P Total U.S. Stock Market ETFITOT1.31M0.00%97.48B USD0.03%$169.66+0.64%
Fidelity Nasdaq Composite Index ETFONEQ605.95K0.01%10.94B USD0.21%$107.81+0.63%
Schwab U.S. Broad Market ETFSCHB521.44K0.00%45.38B USD0.03%$29.91+0.61%
T. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETFTMED193.25K0.60%32.96M USD0.44%$33.8094+2.13%
T. Rowe Price Innovation Leaders ETFTNXT35.56K0.18%19.67M USD0.49%$29.155+1.22%
T. Rowe Price Small Cap ETFTSEE17.75K0.17%10.48M USD0.59%$24.6703+1.40%ARK Genomic Revolution ETFARKGSchwab U.S. Small-Cap ETFSCHAiShares Core S&P Total U.S. Stock Market ETFITOTFidelity Nasdaq Composite Index ETFONEQSchwab U.S. Broad Market ETFSCHBT. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETFTMEDT. Rowe Price Innovation Leaders ETFTNXTT. Rowe Price Small Cap ETFTSEEAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
